From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists have been able to identify patterns of neurodegeneration and create ...

Parkinson's disease is a progressive disorder that develops when the brain cells that produce dopamine (a chemical involved in movement) stop working or die. When this happens, symptoms like slowed ...

Cohorts of patients with idiopathic RBD could also be followed to provide insights into preclinical parkinsonism or dementia.

Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ...

A study from China has reported that Cordyceps sinensis (CS), a traditional Chinese medicinal fungus, can ameliorate idiopathic pulmonary fibrosis (IPF) in mice by inhibiting mitochondrion ...

In December 2024, we received approval to initiate our Phase 1b clinical trial of GT-02287 in people with GBA1 or idiopathic Parkinson's disease. This followed the completion of our study in healthy ...

12 13 Parkinsonism was further divided into three groups: PD (ie, idiopathic parkinsonism) was diagnosed, as in a previous study,9 based on the presence of two or more cardinal signs and after ...

Hydrocephalus associated with shunt malfunction can cause a distinct parkinsonian syndrome with greater dysfunction of projections from the medial substantia nigra to anterior striatum than in ...

Gain Therapeutics (GANX) provided a letter to shareholders from the Company’s President and CEO, Gene Mack, which read in part,”With 2025 ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...